Navigation Links
Anesiva Names Michael L. Kranda as President, Chief Executive Officer and Member of Its Board of Directors
Date:6/16/2008

management," said Mr. Kranda. "I look forward to working with the talented employees of Anesiva to achieve these goals and build long-term value for stockholders."

"The members of the Anesiva board welcome Michael and thank John for his dedicated leadership over the last 8 years," said Mr. Ferguson. "We appreciate John's vision and dedication in leading Anesiva."

"I am proud of the significant accomplishments that the Anesiva team has made over the last several years," said Mr. McLaughlin. "With Michael in place to lead the company forward, I will work closely with him as a consultant to ensure a smooth transition."

About Anesiva's Diverse Pipeline of Pain Products

Anesiva, Inc. is a commercial-stage biopharmaceutical company that seeks to be the leader in the development and commercialization of novel pharmaceutical products for pain management. The company's first product, Zingo(TM), is scheduled for launch later this month in the U.S. for the reduction of pain associated with peripheral venous access procedures in children ages three to 18. The company filed an sNDA with the FDA to expand the label to include adults in March 2008.

The next product in Anesiva's pipeline, Adlea(TM), is currently being evaluated in two pivotal Phase 3 clinical trials to support an indication for the management of acute pain following orthopedic surgery. Adlea has been shown to reduce pain after only a single administration for weeks to months in multiple settings in mid-stage clinical trials for site-specific, acute and chronic, moderate-to-severe pain.

Anesiva is based in South San Francisco, CA. For more information about Anesiva's leadership in the development of products for pain management, and an overview of the clinical challenges being addressed by its product candidates, go to http://www.anesiva.com.

Forward Looking Statements

This press release includes "forward-look
'/>"/>

SOURCE Anesiva, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Anesiva Receives FDA Approval for Zingo(TM), a New, Innovative Product to Reduce Pain Associated with Needle Insertion Procedures in Children
2. Anesiva to Host Conference Call and Webcast Tomorrow to Discuss Encouraging Development in Zingo(TM) Program
3. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
4. Anesiva to Present at BioCenturys NewsMakers in the Biotech Industry Conference on September 6, 2007
5. Anesiva Signs Co-Promotion and Distribution Agreement With Sagent Pharmaceuticals for Zingo(TM) in U.S. Hospitals
6. Anesiva Outlines Comprehensive Commercialization Plan for FDA Approved Product Zingo(TM)
7. Anesiva Raises $45 Million in Common Stock Offering
8. Anesiva Announces Completion of Common Stock Offering
9. Anesiva Announces Fourth Quarter and Year End 2007 Financial Results Conference Call and February 2008 Conference Participation
10. Anesiva Appoints Daniel Janney to Board of Directors
11. Anesiva Announces Fourth Quarter and Year-End 2007 Financial Results and Provides 2008 Outlook
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/1/2015)... NEW YORK , April 1, 2015 /PRNewswire/ ... company advancing protein biologic therapies and oncology supportive ... Company,s 2014 achievements and a strategic update for ... the Company has made in the areas of ... MuGard programs, the FDA clearance of the ProctiGard ...
(Date:4/1/2015)...  Spherix Incorporated (Nasdaq: SPEX ) -- an intellectual ... monetization of intellectual property, today announced that Chardan ... global investment bank specializing in micro, small, and ... Spherix. The report, authored by ... Chardan, was published on March 31, 2015. The ...
(Date:4/1/2015)... Earlier this year, A.J. O’Connor Associates ... association that represents research-based life science organizations in New ... AJO’s Vice President of Business Development & Executive Coach, ... that attracted over 750 attendees. , In one ... old cancer survivor shared his moving story of how, ...
(Date:3/31/2015)... March 31, 2015 CytoSorbents Corporation (NASDAQ ... blood purification to treat critically-ill and cardiac surgery ... summary and reports financial results for the fiscal ... 2014 CytoSorb® product revenues were a record $3.1M, ... 2013 CytoSorb® revenues of $0.8M Highlights for the ...
Breaking Biology Technology:PlasmaTech Biopharmaceuticals Provides Strategic Update for 2015 and Review of 2014 Acheivements 2PlasmaTech Biopharmaceuticals Provides Strategic Update for 2015 and Review of 2014 Acheivements 3PlasmaTech Biopharmaceuticals Provides Strategic Update for 2015 and Review of 2014 Acheivements 4PlasmaTech Biopharmaceuticals Provides Strategic Update for 2015 and Review of 2014 Acheivements 5PlasmaTech Biopharmaceuticals Provides Strategic Update for 2015 and Review of 2014 Acheivements 6Chardan Capital Issues Industry Note Covering Spherix 2Chardan Capital Issues Industry Note Covering Spherix 3HR Consulting Firm, A.J. O'Connor Associates Joins BioNJ – The Vibrant 400 Member Strong Life Sciences Industry Association - and Attends its Annual Dinner 2CytoSorbents Reports Record 2014 Revenue 2CytoSorbents Reports Record 2014 Revenue 3CytoSorbents Reports Record 2014 Revenue 4CytoSorbents Reports Record 2014 Revenue 5CytoSorbents Reports Record 2014 Revenue 6CytoSorbents Reports Record 2014 Revenue 7CytoSorbents Reports Record 2014 Revenue 8CytoSorbents Reports Record 2014 Revenue 9CytoSorbents Reports Record 2014 Revenue 10CytoSorbents Reports Record 2014 Revenue 11
... Pharmaceuticals, Inc.,a privately held biopharmaceutical company developing anti-inflammatory,drugs, ... varespladib (A-002) at,the American Heart Association (AHA) Annual ... Phase II trials in varespladib for the,treatment of ... and its,collaborators released new data from the Phase ...
... November 11 , - Revenues Expected to be ... The Binding Site Limited ("The Binding Site" or the ... update for the year ended 30th September 2008. The ... Revenues are expected to be GBP38.9 million, representing ...
... Cardium Therapeutics,(Amex: CXM ) today reported financial results and ... revised business strategies,for its three operating units: (1) InnerCool Therapies, ... (Logo: http://www.newscom.com/cgi-bin/prnh/20051018/CARDIUMLOGO ), ... InnerCool ...
Cached Biology Technology:Anthera's Varespladib Demonstrates Significant Anti-Inflammatory Effect and LDL Reduction in Patients With Coronary Heart Disease 2The Binding Site Announces Trading Update for Year Ended September 30th 2008 2The Binding Site Announces Trading Update for Year Ended September 30th 2008 3Cardium Reports on Third Quarter 2008 Financial Results and Revised Business Strategies for Operating Units 2Cardium Reports on Third Quarter 2008 Financial Results and Revised Business Strategies for Operating Units 3Cardium Reports on Third Quarter 2008 Financial Results and Revised Business Strategies for Operating Units 4Cardium Reports on Third Quarter 2008 Financial Results and Revised Business Strategies for Operating Units 5Cardium Reports on Third Quarter 2008 Financial Results and Revised Business Strategies for Operating Units 6Cardium Reports on Third Quarter 2008 Financial Results and Revised Business Strategies for Operating Units 7Cardium Reports on Third Quarter 2008 Financial Results and Revised Business Strategies for Operating Units 8Cardium Reports on Third Quarter 2008 Financial Results and Revised Business Strategies for Operating Units 9Cardium Reports on Third Quarter 2008 Financial Results and Revised Business Strategies for Operating Units 10Cardium Reports on Third Quarter 2008 Financial Results and Revised Business Strategies for Operating Units 11
(Date:3/31/2015)... March 31, 2015  Elephant Talk Communications Corp. (NYSE ... provider of Software Defined Network Architecture (ET Software DNA® ... revenue of approximately $20.4 million for the year ended ... million for the year ended December 31, 2013. ... Company had completed its multi-year transition away from its ...
(Date:3/30/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/lc9bnl/global_gesture ... Gesture Recognition Market in Automotive Sector 2014-2018" report ... Global Gesture Recognition market in Automotive Sector to grow ... Gesture recognition is the ability of a ... an individual. Gesture recognition technology can be 2D-based or ...
(Date:3/24/2015)... and Markets ( http://www.researchandmarkets.com/research/hdgz7h/global_iris ) has announced ... 2015-2019" report to their offering. The ... at a CAGR of 23.5 percent over the period ... and the growth prospects of the Global Iris Recognition ... size, the report considers the revenue generated from sales ...
Breaking Biology News(10 mins):Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 2Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 3Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 4Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 5Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 6Global Gesture Recognition Market in Automotive Sector Report 2015 - Growing Number of Partnerships 2Global Iris Recognition Market 2015-2019 with 3M Cogent, Bioenable Technologies, Cross Match Technology, Iris ID Systems & Safran Dominating 2
... by Scripps Research Professor Benjamin Cravatt, Ph.D., is ... The Journal of Biological Chemistry. , The new ... suggested-for the biosynthesis of neurotransmitter lipids, N-acyl ethanolamines ... The high activity of the enzyme a/b hydrolase4 ...
... bacteria, viruses and other dangerous substances in hospitals, airplanes ... easy as wiping a napkin or paper towel across ... "It's very inexpensive, it wouldn't require that someone be ... activated for whatever you want to find," said Margaret ...
... specifically targets mutant enzymes or "oncoproteins" that have run ... as these drugs are, cancer cells with their backs ... A major goal of cancer research is to frustrate ... issue of Cancer Cell, investigators at the Salk Institute ...
Cached Biology News:Study shows enzyme builds neurotransmitters via newly discovered pathway 2Biodegradable napkin -- featuring sensitive nanofibers -- may quickly detect biohazards 2Distinguishing friend from foe in the battle against cancer 2Distinguishing friend from foe in the battle against cancer 3
Improve inventory management with stainless steel red cell canisters; ensure product safety with CO2 or LN2 backup systems. A complete solution for your blood banking needs....
... S and 135 S steam sterilizers with their ... the advantages of a double-walled device - low ... and drying by built-in jacket heater - with ... The chamber is free of furnishings and feed ...
... SuperScript™ II RNase H- Reverse Transcriptase (RT) ... RNase H- RT. It is a DNA ... from single-stranded RNA DNA or an RNA:DNA ... the introduction of point mutations rather than ...
Request Info...
Biology Products: